查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2030085

瑞德西韋市場－全球產業規模、佔有率、趨勢、機會與預測：按劑型、給藥途徑、病患年齡、應用、分銷管道、地區和競爭格局分類，2021-2031年

Remdesivir Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Dosage Form, By Route of Administration, By Patient Age, By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球瑞德西韋市場預計將從 2025 年的 49.2 億美元成長到 2031 年的 70.7 億美元，複合年成長率為 6.23%。

由吉利德科學公司研發的這種頻譜抗病毒前驅藥物，以Veklury為商品名上市，透過阻斷病毒的RNA依賴性RNA聚合酵素來抑制病毒複製。市場擴張主要得益於呼吸道疾病和其他病毒性疾病對強效抗病毒療法的持續需求，而政府對疾病控制計畫的大力投入也推動了這項需求。此外，藥物研發的不斷進步在提高藥物療效和拓展其臨床應用方面發揮著至關重要的作用。

市場概覽
預測期 2027-2031
市場規模：2025年 49.2億美元
市場規模：2031年 70.7億美元
複合年成長率：2026-2031年 6.23%
成長最快的細分市場 靜脈
最大的市場 北美洲

另一方面，重症病例和相關住院人數的下降降低了對新冠病毒抗病毒藥物的需求，阻礙了市場成長。其他持續存在的障礙包括病毒抗藥性的產生以及藥物研發的高昂成本。同時，根據美國醫學會（AMA）的數據，預計到2023年，美國醫療保健支出將成長7.5%，達到4.9兆美元。這一支出成長為整個製藥業及其抗病毒藥物領域提供了基礎性支撐。

市場促進因素

病毒性疾病的持續全球蔓延是瑞德西韋市場的主要成長動力。包括季節性流感和新型冠狀病毒（SARS-CoV-2）新變種在內的各種呼吸道病原體的持續傳播，凸顯了對易於獲取且療效顯著的抗病毒療法的迫切需求。這些病毒給全球醫療衛生基礎設施帶來了沉重負擔，也增加了對能夠降低住院率和預防嚴重併發症的藥物的需求。 2026年2月，美國疾病管制與預防中心（CDC）指出，在2024年10月1日至2025年7月5日期間，美國約有29萬至45萬例與新冠肺炎相關的住院病例，並強調瑞德西韋等藥物在治療急性感染疾病仍然至關重要。

強而有力的政府支持和積極主動的疫情防範計畫進一步推動了瑞德西韋產業的發展。世界各國都在大力投資建設和儲備抗病毒藥物，以更好地應對未來潛在的突發公共衛生事件，從而確保藥物研發和採購的資金支持。例如，美國生物醫學高級研究與發展局（BARDA）於2026年2月設立了1億美元的“SMART抗病毒獎”，旨在加速頻譜治療方法的研發，這體現了公共部門對先進抗病毒解決方案的持續投入。同時，醫藥產業的全面投資趨勢也影響這些藥物的供應。複雜的金融生態系統驅動市場發展，例如強生公司於2026年3月宣布將2025會計年度的研發預算削減15%至146.65億美元。

市場挑戰

阻礙全球瑞德西韋產業擴張的一大障礙是新冠病毒特異性抗病毒藥物需求的下降。隨著全球重症病例及相關住院人數的持續減少，對瑞德西韋等速效治療藥物的迫切需求也顯著降低。因此，世界各地的醫療機構都在縮減該藥物的使用和採購規模。

這種興趣下降的影響在瑞德西韋近期的財務表現中得到了清晰的體現。根據吉利德科學公司的報告，瑞德西韋（Veklury）2025會計年度的全年銷售額為9.11億美元，較上年大幅下降49%。銷售額的急劇下降主要是因為新冠肺炎相關住院人數的減少。最終，這一趨勢表明，新冠肺炎疫情情勢的變化正在顯著降低那些依賴治療嚴重病毒症狀的治療方法的商業性永續性。

市場趨勢

國際瑞德西韋市場正受到專利到期和生物相似藥競爭加劇的影響，市場格局也不斷變化。雖然其主要成分「Veklury」的專利有效期至2030年代中期，但目前市場上的專利糾紛日益增多，某些地區的壟斷局面也即將終結。在此背景下，學名藥生產商正積極尋求進入市場的途徑，而原廠藥開發商則被迫竭力保護其智慧財產權。這種競爭可能導致價格較低的替代藥物進入市場，進而影響瑞德西韋在多個地區的市佔率和定價。例如，JUVE Patent曾報道，2025年8月，吉利德科學公司在米蘭中央區法院提起訴訟，試圖宣告中國軍事醫學學院持有的一項專利無效。

此外，瑞德西韋與其他老藥新用及抗病毒藥物聯合應用的聯合療法的興起，是該行業的一項變革性趨勢。由於病毒感染疾病高度複雜，這種聯合療法旨在透過協同作用克服抗藥性，從而提高整體療效，擴大靶向病毒範圍，並改善患者預後。這些醫學進步正在擴大瑞德西韋的效用，使其應用超越最初的適應症，並確保其繼續作為現代治療策略中的主力藥物。一篇發表於2025年8月29日《感染與化療雜誌》（Journal of Infect Chemother）的論文也印證了這一成功：瑞德西韋聯合恩西瑞韋或尼馬瑞韋/Ritonavir，作為一線治療方案，在92%的骨髓惡性腫瘤患者中取得了成功（13例中有12例有效）。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球瑞德西韋市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依劑型（凍乾液體、冷凍液體）
    • 給藥途徑（靜脈注射、吸入）
    • 患者年齡層成（老年人、成人、兒童）
    • 依應用（SARS-CoV-2 (COVID-19)、MERS-CoV、伊波拉、SARS-CoV）
    • 分銷管道（醫院、診所、藥局、藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美瑞德西韋市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲瑞德西韋市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：瑞德西韋亞太地區市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：瑞德西韋在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：瑞德西韋在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球瑞德西韋市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Gilead Sciences, Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Hetero Labs Limited
  • Mylan NV
  • Sun Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited
  • Jubilant Pharmova Limited
  • Aurobindo Pharma Limited
  • Fujifilm Toyama Chemical Co., Ltd.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 4714

The Global Remdesivir market is anticipated to expand from USD 4.92 billion in 2025 to USD 7.07 billion by 2031, reflecting a compound annual growth rate (CAGR) of 6.23%. Sold under the brand name Veklury, this broad-spectrum antiviral prodrug created by Gilead Sciences works by blocking viral RNA-dependent RNA polymerase to halt viral replication. Market expansion is largely fueled by the persistent demand for potent antiviral treatments against respiratory and other viral illnesses, supported by strong government funding for disease management programs. Additionally, continuous progress in pharmaceutical research plays a key role by improving drug effectiveness and broadening its clinical uses.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 4.92 Billion
Market Size 2031USD 7.07 Billion
CAGR 2026-20316.23%
Fastest Growing SegmentIntravenous
Largest MarketNorth America

Conversely, market growth faces obstacles due to a declining need for COVID-19-targeted antivirals, as severe cases and related hospital admissions have dropped. Other persistent barriers include the development of viral resistance and the high expenses tied to pharmaceutical innovation. Meanwhile, data from the American Medical Association indicates that healthcare expenditures in the United States grew by 7.5% in 2023 to hit $4.9 trillion; this increased spending provides underlying support for the overall pharmaceutical sector and its antiviral segment.

Market Driver

The ongoing prevalence of viral diseases worldwide acts as a major growth engine for the Remdesivir market. The relentless spread of various respiratory pathogens, such as seasonal flu and novel SARS-CoV-2 variants, highlights the urgent need for accessible and potent antiviral therapies. Because these viruses place immense strain on global healthcare infrastructure, there is a strong demand for medications capable of lowering hospitalization rates and preventing severe health complications. The Centers for Disease Control and Prevention noted in February 2026 that the United States saw roughly 290,000 to 450,000 COVID-19-related hospital admissions between October 1, 2024, and July 5, 2025, emphasizing the enduring necessity for drugs like Remdesivir to treat acute infections.

Robust government backing and proactive pandemic readiness programs further stimulate the Remdesivir industry. Nations across the globe are heavily funding the creation and accumulation of antiviral reserves to better manage potential future health emergencies, thereby securing financial support for drug research and procurement. For instance, in February 2026, BARDA introduced the $100 million SMART Antiviral Prize to speed up the creation of broad-spectrum treatments, demonstrating a continued public sector dedication to advanced antiviral solutions. At the same time, overarching investment trends in the pharmaceutical sector impact the availability of these drugs, as seen when Johnson & Johnson announced a 15% cut in its 2025 R&D budget to $14.665 billion in March 2026, illustrating the complex financial ecosystem driving market progress.

Market Challenge

A major obstacle hindering the expansion of the global Remdesivir industry is the dropping demand for antiviral medications tailored specifically to COVID-19. With severe cases of the virus and their corresponding hospital admissions on a steady downward trajectory globally, the urgent requirement for fast-acting treatments like Veklury has notably faded. Consequently, global healthcare networks have scaled back their usage and purchasing of the medication.

The consequences of this waning interest are clearly reflected in Remdesivir's recent financial outcomes. Gilead Sciences reported that Veklury generated $911 million in revenue throughout 2025, which marks a steep 49% drop compared to the previous year's figures. This sharp revenue contraction was mainly caused by the falling number of hospitalizations tied to the virus. Ultimately, this pattern demonstrates that the shifting epidemiological nature of COVID-19 actively reduces the commercial viability of therapies reliant on treating severe viral symptoms.

Market Trends

The international Remdesivir sector is being heavily shaped by shifting post-patent dynamics and a rise in biosimilar rivalry. Even though the primary compound patents for Veklury are valid until the mid-2030s, the market is currently experiencing heightened patent disputes and the end of specific regional monopolies. This environment forces original creators to fiercely protect their intellectual property, just as generic drug makers aggressively seek pathways to enter the market. Consequently, this competitive tension may result in cheaper alternatives becoming available, which could impact the market share and pricing of Remdesivir across multiple regions. Illustrating this IP struggle, JUVE Patent noted that Gilead Sciences initiated a revocation lawsuit in August 2025 at the Central Division's Milan branch against a patent owned by the Chinese Academy of Military Medical Sciences.

Additionally, the rise of combination treatments that pair Remdesivir with other repurposed medications or antivirals is a vital trend transforming the industry. Because viral infections are highly complex, this approach is designed to boost overall effectiveness, widen the range of targeted viruses, and deliver better patient outcomes by leveraging synergistic interactions to defeat drug resistance. These medical strides are intended to push Remdesivir's usefulness past its original applications, ensuring it remains a staple in modern therapeutic strategies. Highlighting this success, an August 29, 2025, publication in J Infect Chemother revealed that using Remdesivir in conjunction with ensitrelvir or nirmatrelvir/ritonavir was successful in 92% of cases (12 out of 13) when utilized as a primary COVID-19 therapy for patients suffering from hematological malignancies.

Key Market Players

  • Gilead Sciences, Inc.
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Hetero Labs Limited
  • Mylan N.V.
  • Sun Pharmaceutical Industries Limited
  • Zydus Lifesciences Limited
  • Jubilant Pharmova Limited
  • Aurobindo Pharma Limited
  • Fujifilm Toyama Chemical Co., Ltd.

Report Scope

In this report, the Global Remdesivir Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Remdesivir Market, By Dosage Form

  • Lyophilized Solution
  • Frozen Solution

Remdesivir Market, By Route of Administration

  • Intravenous
  • Inhalation

Remdesivir Market, By Patient Age

  • Geriatric
  • Adult
  • Pediatric

Remdesivir Market, By Application

  • SARS-CoV-2 (COVID-19)
  • MERS-CoV
  • Ebola
  • SARS-CoV

Remdesivir Market, By Distribution Channel

  • Hospitals
  • Clinics
  • Drug Stores
  • Pharmacies

Remdesivir Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Remdesivir Market.

Available Customizations:

Global Remdesivir Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Remdesivir Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Dosage Form (Lyophilized Solution, Frozen Solution)
    • 5.2.2. By Route of Administration (Intravenous, Inhalation)
    • 5.2.3. By Patient Age (Geriatric, Adult, Pediatric)
    • 5.2.4. By Application (SARS-CoV-2 (COVID-19), MERS-CoV, Ebola, SARS-CoV)
    • 5.2.5. By Distribution Channel (Hospitals, Clinics, Drug Stores, Pharmacies)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Remdesivir Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Dosage Form
    • 6.2.2. By Route of Administration
    • 6.2.3. By Patient Age
    • 6.2.4. By Application
    • 6.2.5. By Distribution Channel
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Remdesivir Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Dosage Form
        • 6.3.1.2.2. By Route of Administration
        • 6.3.1.2.3. By Patient Age
        • 6.3.1.2.4. By Application
        • 6.3.1.2.5. By Distribution Channel
    • 6.3.2. Canada Remdesivir Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Dosage Form
        • 6.3.2.2.2. By Route of Administration
        • 6.3.2.2.3. By Patient Age
        • 6.3.2.2.4. By Application
        • 6.3.2.2.5. By Distribution Channel
    • 6.3.3. Mexico Remdesivir Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Dosage Form
        • 6.3.3.2.2. By Route of Administration
        • 6.3.3.2.3. By Patient Age
        • 6.3.3.2.4. By Application
        • 6.3.3.2.5. By Distribution Channel

7. Europe Remdesivir Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Dosage Form
    • 7.2.2. By Route of Administration
    • 7.2.3. By Patient Age
    • 7.2.4. By Application
    • 7.2.5. By Distribution Channel
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Remdesivir Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Dosage Form
        • 7.3.1.2.2. By Route of Administration
        • 7.3.1.2.3. By Patient Age
        • 7.3.1.2.4. By Application
        • 7.3.1.2.5. By Distribution Channel
    • 7.3.2. France Remdesivir Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Dosage Form
        • 7.3.2.2.2. By Route of Administration
        • 7.3.2.2.3. By Patient Age
        • 7.3.2.2.4. By Application
        • 7.3.2.2.5. By Distribution Channel
    • 7.3.3. United Kingdom Remdesivir Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Dosage Form
        • 7.3.3.2.2. By Route of Administration
        • 7.3.3.2.3. By Patient Age
        • 7.3.3.2.4. By Application
        • 7.3.3.2.5. By Distribution Channel
    • 7.3.4. Italy Remdesivir Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Dosage Form
        • 7.3.4.2.2. By Route of Administration
        • 7.3.4.2.3. By Patient Age
        • 7.3.4.2.4. By Application
        • 7.3.4.2.5. By Distribution Channel
    • 7.3.5. Spain Remdesivir Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Dosage Form
        • 7.3.5.2.2. By Route of Administration
        • 7.3.5.2.3. By Patient Age
        • 7.3.5.2.4. By Application
        • 7.3.5.2.5. By Distribution Channel

8. Asia Pacific Remdesivir Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Dosage Form
    • 8.2.2. By Route of Administration
    • 8.2.3. By Patient Age
    • 8.2.4. By Application
    • 8.2.5. By Distribution Channel
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Remdesivir Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Dosage Form
        • 8.3.1.2.2. By Route of Administration
        • 8.3.1.2.3. By Patient Age
        • 8.3.1.2.4. By Application
        • 8.3.1.2.5. By Distribution Channel
    • 8.3.2. India Remdesivir Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Dosage Form
        • 8.3.2.2.2. By Route of Administration
        • 8.3.2.2.3. By Patient Age
        • 8.3.2.2.4. By Application
        • 8.3.2.2.5. By Distribution Channel
    • 8.3.3. Japan Remdesivir Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Dosage Form
        • 8.3.3.2.2. By Route of Administration
        • 8.3.3.2.3. By Patient Age
        • 8.3.3.2.4. By Application
        • 8.3.3.2.5. By Distribution Channel
    • 8.3.4. South Korea Remdesivir Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Dosage Form
        • 8.3.4.2.2. By Route of Administration
        • 8.3.4.2.3. By Patient Age
        • 8.3.4.2.4. By Application
        • 8.3.4.2.5. By Distribution Channel
    • 8.3.5. Australia Remdesivir Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Dosage Form
        • 8.3.5.2.2. By Route of Administration
        • 8.3.5.2.3. By Patient Age
        • 8.3.5.2.4. By Application
        • 8.3.5.2.5. By Distribution Channel

9. Middle East & Africa Remdesivir Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Dosage Form
    • 9.2.2. By Route of Administration
    • 9.2.3. By Patient Age
    • 9.2.4. By Application
    • 9.2.5. By Distribution Channel
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Remdesivir Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Dosage Form
        • 9.3.1.2.2. By Route of Administration
        • 9.3.1.2.3. By Patient Age
        • 9.3.1.2.4. By Application
        • 9.3.1.2.5. By Distribution Channel
    • 9.3.2. UAE Remdesivir Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Dosage Form
        • 9.3.2.2.2. By Route of Administration
        • 9.3.2.2.3. By Patient Age
        • 9.3.2.2.4. By Application
        • 9.3.2.2.5. By Distribution Channel
    • 9.3.3. South Africa Remdesivir Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Dosage Form
        • 9.3.3.2.2. By Route of Administration
        • 9.3.3.2.3. By Patient Age
        • 9.3.3.2.4. By Application
        • 9.3.3.2.5. By Distribution Channel

10. South America Remdesivir Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Dosage Form
    • 10.2.2. By Route of Administration
    • 10.2.3. By Patient Age
    • 10.2.4. By Application
    • 10.2.5. By Distribution Channel
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Remdesivir Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Dosage Form
        • 10.3.1.2.2. By Route of Administration
        • 10.3.1.2.3. By Patient Age
        • 10.3.1.2.4. By Application
        • 10.3.1.2.5. By Distribution Channel
    • 10.3.2. Colombia Remdesivir Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Dosage Form
        • 10.3.2.2.2. By Route of Administration
        • 10.3.2.2.3. By Patient Age
        • 10.3.2.2.4. By Application
        • 10.3.2.2.5. By Distribution Channel
    • 10.3.3. Argentina Remdesivir Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Dosage Form
        • 10.3.3.2.2. By Route of Administration
        • 10.3.3.2.3. By Patient Age
        • 10.3.3.2.4. By Application
        • 10.3.3.2.5. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Remdesivir Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Gilead Sciences, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Cipla Limited
  • 15.3. Dr. Reddy's Laboratories Limited
  • 15.4. Hetero Labs Limited
  • 15.5. Mylan N.V.
  • 15.6. Sun Pharmaceutical Industries Limited
  • 15.7. Zydus Lifesciences Limited
  • 15.8. Jubilant Pharmova Limited
  • 15.9. Aurobindo Pharma Limited
  • 15.10. Fujifilm Toyama Chemical Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer